Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 6:50 PM
Ignite Modification Date:
2025-12-24 @ 6:50 PM
NCT ID:
NCT05760157
Eligibility Criteria:
Inclusion Criteria:
1. Age 18-75 years old (including threshold), gender unlimited
2. acute ST-segment elevation myocardial infarction was diagnosed, and the following two criteria were met: A) ischemic chest pain lasting ≥30 min；B) ECG indicating ST-segment elevation ≥0.1 mV in two or more limb leads and/or ≥0.2 mV in two or more adjacent chest leads
3. Coronary angiography confirmed that the culprit's vessel was located in the anterior descending branch, and the proximal and middle segments of the anterior descending branch were occluded (TIMI blood flow 0 or 1), Or TIMI blood flow grade 2 with obvious thrombus (TIMI thrombus score ≥ 2 points, which is determined after the guide wire passes and restores the forward blood flow. The TIMI thrombus score is determined as follows: 0 point: no thrombus is determined；1 point: blurred thrombus image is visible；2 point: clear thrombus image, but the length of the thrombus image is less than 1/2 vessel diameter；3 point: clear thrombus image, the length of the thrombus image is 1/2\~2 times the vessel diameter；4 point: clear thrombus image, the thrombus image is more than 2 times the vessel diameter；5 points : complete occlusion of blood vessels)
4：Emergency PCI revascularization was completed within 12 hours after the occurrence of myocardial infarction. Postoperative angiography confirmed that residual stenosis was less than 50%.
5: Sign the informed consent form voluntarily
Exclusion Criteria:
1. Severe heart failure at discharge (NYHA III/IV, EF\<30%)；Or patients with severe hemodynamic instability and cardiogenic shock, defined as systolic blood pressure\<90 mmHg, and/or cardiac index\<2.2 L/min/m2 during continuous (\>30 minutes) attacks, identified as secondary cardiac insufficiency, and/or requiring extraintestinal muscle strength or vasoconstrictor or mechanical support to maintain blood pressure and cardiac index above these specified levels.
2. patients undergoing coronary artery bypass grafting
3. Patients with mechanical complications after myocardial infarction
4. prolonged or invasive cardiopulmonary resuscitation
5. Patients with acute pericarditis, infective endocarditis, severe valvular heart disease and cardiomyopathy
6. Serious liver and kidney failure and other diseases, mental disorders or cognitive disorders
7. The expected survival of tumor patients is less than 2 years
8. patients who are participating in other interventional clinical trials
9. Those who refuse to participate or are clearly unable to complete the follow-up according to the established time point.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT05760157
Study Brief:
Protocol Section:
NCT05760157